Previous works have demonstrated that the combined inhibition of HDAC6 and Hh pathway using TubA and cyclo treatment effectively reduces glioma cells’ clonogenicity and migration capacity [17,37]. This evidence concerns the gene HDAC6 and central nervous system cancer.